FOCUS COLUMN
By Pauline Farmer-Koppenol
This article appears on Page 7
Since KSR Int'l Co. v. Teleflex Inc., 127 S. Ct. 1727 (U.S. 2007), the Court of Appeals for the Federal Circuit has rendered several decisions where the obviousness of a chemical compound was at issue. Patents for chemical compounds are at the core of patent protection for small-molecule drugs and therefore the impact of KSR on obviousness ...
To continue reading, please subscribe.
For only $95 a month (the price of 2 article purchases)
Receive unlimited article access and full access to our archives,
Daily Appellate Report, award winning columns, and our
Verdicts and Settlements.
Or
$795 for an entire year!
For only $95 a month (the price of 2 article purchases)
Receive unlimited article access and full access to our archives,
Daily Appellate Report, award winning columns, and our
Verdicts and Settlements.
Or
$795 for an entire year!
Or access this article for $45
(Purchase provides 7-day access to this article. Printing, posting or downloading is not allowed.)
Already a subscriber?
Sign In